Israel - English - Ministry of Health

eisai israel ltd., israel - eribulin as mesilate - solution for injection - eribulin as mesilate 0.44 mg/ml - eribulin - eribulin - halaven is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.

Israel - English - Ministry of Health

eisai israel ltd., israel - eribulin as mesilate - solution for injection - eribulin as mesilate 0.44 mg/ml - eribulin - eribulin - halaven is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.

Singapore - English - HSA (Health Sciences Authority)

eisai (singapore) pte. ltd. - eribulin mesylate - injection, solution - 1.0 mg/vial - eribulin mesylate 1.0 mg/vial

European Union - English - EMA (European Medicines Agency)

eisai gmbh - eribulin - breast neoplasms; liposarcoma - antineoplastic agents - halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eisai ltd - eribulin - solution for injection - .44mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eisai ltd - eribulin - solution for injection - .44mg/1ml

Israel - English - Ministry of Health

neopharm scientific ltd - eribulin as mesilate - solution for injection - eribulin as mesilate 0.44 mg/ml - eribulin - halaven is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.

Israel - English - Ministry of Health

eisai israel ltd., israel - eribulin as mesilate - solution for injection - eribulin as mesilate 0.44 mg/ml - eribulin - halaven is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

advanz pharma limited - eribulin mesylate - solution for injection - eribulin

Canada - English - Health Canada

eisai limited - eribulin mesylate - solution - 0.5mg - eribulin mesylate 0.5mg - antineoplastic agents